CJC-1295 No DAC 5mg and Ipamorelin 5mg Blend for Research
What is CJC-1295 No DAC?
What is Ipamorelin?
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist, a pentapeptide known for its specificity in stimulating GH release without affecting other hormones like cortisol or prolactin. With a half-life of about 2 hours, Ipamorelin induces rapid, short-lived GH spikes, complementing the sustained action of CJC-1295 No DAC. Research, including a 1998 study in the European Journal of Endocrinology, highlights Ipamorelin’s role in counteracting glucocorticoid-induced bone loss and improving gastric motility, underscoring its versatility in metabolic and musculoskeletal studies.
Synergistic Power of the CJC-1295 No DAC and Ipamorelin Blend
The CJC-1295 No DAC and Ipamorelin blend leverages complementary mechanisms to maximize GH secretion in research subjects. CJC-1295 No DAC enhances the amplitude of GH pulses by acting on GHRH receptors, while Ipamorelin amplifies the frequency of these pulses through ghrelin receptor activation. This dual-action approach results in a 3-5 fold increase in GH release compared to either peptide alone, as noted in clinical research settings. The blend’s synergy creates a higher baseline for GH levels while preserving the natural pulsatile secretion pattern, offering researchers a robust platform to study:
-
Muscle Growth and Repair: Enhanced protein synthesis and nitrogen retention for lean muscle development.
-
Fat Metabolism: Accelerated lipolysis and improved insulin sensitivity for fat loss studies.
-
Recovery Processes: Faster tissue repair and reduced recovery times in non-human models.
-
Metabolic Function: Improved bowel motility, bone density, and cognitive performance.
